Radius Health (RDUS) Misses Q1 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Tesla acquires AI hardware company for up to $2 billion in stock
Radius Health, Inc. First Quarter 2022 Results
May 5, 2022 7:30 AM EDTQ1 2022 TYMLOS® product net revenue of $43 million vs. $45 million in Q1 2021
° Q1 results: in-line with previously guided 1H 2022 company target of $97 million
° Reiterating FY 2022 TYMLOS Net Revenue guidance of $232 million
° Seasonality, as previously announced: 42% of net revenue in 1H and 58% in 2H 2022
° Patient Growth: average active patients on therapy increased by 4% compared to Q1 2021Productivity improvement continued: revenue per commercial headcount up 32% vs. Q1 2021TYMLOS for the Male indication: sNDA filed in Q1 2022 with launch planned for early Q1 2023Additional patent granted by USPTO for TYMLOS: extending exclusivity to January 10,... More
